TISSIUM
74, Rue du Faubourg Saint-Antoine
Paris
75012
France
Tel: 33-1-76-21-72-28
Website: http://www.tissium.com/
45 articles about TISSIUM
-
First Patients Treated with TISSIUM's Atraumatic Hernia Repair System
9/12/2023
TISSIUM announced the first clinical use of TISSIUM's Adhesive Hernia Repair System in patients undergoing laparoscopic ventral hernia repair as part of the ALPHA clinical study taking place in Belgium.
-
TISSIUM Obtains a Non-Dilutive Financing of €4.2 Million Within the Framework of the "FRANCE 2030" Plan
6/15/2023
TISSIUM, a private medtech specializing in the development of programmable biomorphic polymers for tissue reconstruction, announces it has obtained a non-dilutive financing of €4.2 million from Bpifrance as part of the "France 2030" plan to extend its production capacity for "large volume" syringes.
-
TISSIUM Raises €50M in Series D Funding to Finance its Commercial Launch and Platform Extension
5/23/2023
TISSIUM announced it has closed a Series D round of financing, raising €50 million from new and existing international investors, including Fonds Stratégique des Transitions, managed by ISALT, Merieux Developpement and returning Cathay Health, Credit Mutuel Innovation and Sofinnova Partners.
-
TISSIUM Appoints Alex Milstein as Chief Medical Officer
1/17/2023
TISSIUM, a privately-owned medical technology company developing a portfolio of biomorphic programmable polymers for tissue reconstruction, announced it has appointed Dr. Alex Milstein as its Chief Medical Officer.
-
TISSIUM Appoints Sara Toyloy as Independent Board Member
9/26/2022
TISSIUM, a privately-owned medtech company developing biomorphic programmable polymers for tissue reconstruction, announced it has appointed Sara Toyloy as its fourth independent member of the Board of Directors.
-
Tissium Appoints Maria Sainz as Independent Board Member
7/12/2022
TISSIUM, a privately-owned medtech company developing biomorphic programmable polymers for tissue reconstruction, announced it has appointed Maria Sainz as an independent member of the Board of Directors.
-
BioSpace Movers & Shakers, Jan. 14
1/14/2022
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
TISSIUM Appoints Ruth Krestin as Vice President of Portfolio Strategy
1/10/2022
TISSIUM, a privately-owned medtech company developing biomorphic programmable polymers for tissue reconstruction, announced it has appointed Ruth Krestin as Vice President of Portfolio Strategy within TISSIUM.
-
TISSIUM to Present Study Results at the Hernia 2021 European Hernia Society – American Hernia Society Joint Congress
10/6/2021
TISSIUM will present an e-poster on its research on a novel, atraumatic, and consistent hernia mesh fixation device at the Hernia 2021 European Hernia Society – American Hernia Society Joint Congress. The event is scheduled to be held virtually and in-person from October 13 – October 16, 2021 in Copenhagen, Denmark.
-
TISSIUM to Present Study Results at the 76th Annual Meeting of the American Society for Surgery of the Hand
9/24/2021
TISSIUM, a privately-owned medtech company developing biomorphic programmable polymers for tissue reconstruction, has announced its research has been selected for presentation within the scientific program at the 76th Annual Meeting of the American Society for Surgery of the Hand.
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
TISSIUM Raises €50M in Series C Financing to Propel its Platform to Commercial Stage
8/31/2021
TISSIUM, a privately-owned medtech company developing biomorphic programmable polymers for tissue reconstruction, announced it has closed a Series C round of financing, raising €50 million from new and existing international investors.
-
BioSpace Movers & Shakers, July 2
7/2/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
TISSIUM Appoints Romain Attard as Chief Financial Officer
7/1/2021
TISSIUM, a privately-owned medtech company developing biomorphic programmable polymers for tissue reconstruction, announced Romain Attard has been appointed Chief Financial Officer of TISSIUM.
-
BioSpace Movers & Shakers, March 26
3/26/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.
-
TISSIUM Selected for French Tech 120 Program
2/9/2021
TISSIUM, a privately-owned medtech company developing biomorphic programmable polymers for tissue reconstruction, announced today it has been named a French Tech 120 company for the 2021 program.
-
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
-
BioSpace Movers & Shakers, Dec. 18
12/18/2020
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
TISSIUM Receives FDA Investigational Device Exemption for Vascular Sealant
11/17/2020
TISSIUM, a privately-owned medtech company developing biomorphic programmable polymers for tissue reconstruction, announced today it has received approval from the U.S. Food and Drug Administration for its Investigational Device Exemption application for its vascular sealant. The approval is the most recent validation of TISSIUM’s efforts to de